MEA Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
- Published Date: 2022-12-24
- Report ID: 143413
- Pages: 225
-
Format:
Short Description
Middle East and Africa Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
Natural killer (NK) cells are the large granular lymphocytes which have the ability to quickly respond to a pathological challenge. Natural killer cells are the important component of innate immune system and play an important role in generating immune response against the malignancies and infectious diseases caused by viral pathogens. Natural killer (NK) cells have been recognized to induce direct killing of targeted cells involving cancer cells. These have the ability to recognize the multitude of infected cells without being dependent on a single antigen expressing cells.
NK cells secrete cytokines and chemokines which recruit other immune cells such as T cells and B cells which enhances the immune response against the tumor cells. As Natural killer (NK) cells do not express T cell receptors, they induce low risk of graft-versus-host disease.
The effectiveness of NK cells therapies can be also be enhanced by genetically modified the NK cells so as to obtain highly specific and persistent cell lines. NK cell therapies can also be used with mono-clonal antibodies and T-cell therapies which again enhances its anti-tumor activity.
Increase in usage of natural killer cells for the treatment of cancer and infectious disease is a key factor responsible for market growth. Along with this rise in patients population with chronic disease and rise in the awareness about immunotherapies boosting the market growth.
Market Segmentation:
Natural killer (NK) cell therapeutics market is categorized into four notable segments which are based on therapeutics, approaches, application, end user, and distribution channel.
On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies
On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.
On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others.
On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes
On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others
Market Players
The key market players for natural killer (NK) cell therapeutics market are listed below:
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Kiadis Pharma
Cytovia Therapeutics
Nkarta, Inc.
Nektar
ImmunityBio, Inc.
Brink Biologics, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
PersonGen BioTherapeutics
Innate Pharma, Inc.
INmuneBIO
Gamida Cell
Acepodia Inc.
Affimed GmbH
Multimmune GmbH
iCell Gene Therapeutics
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals Inc.
TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET 30
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 33
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 DBMR TRIPOD DATA VALIDATION MODEL 38
2.6 MULTIVARIATE MODELLING 41
2.7 THERAPEUTICS LIFELINE CURVE 41
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.9 DBMR MARKET POSITION GRID 43
2.10 SECONDARY SOURCES 45
2.11 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
3.1 EPIDEMIOLOGY 51
3.2 PESTEL ANALYSIS 52
3.3 PORTERS FIVE FORCES MODEL 53
3.4 INDUSTRIAL INSIGHTS: 54
3.5 PIPELINE ANALYSIS 56
4 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: REGULATIONS 57
5 MARKET OVERVIEW 59
5.1 DRIVERS 61
5.1.1 INCREASE IN USAGE OF NATURAL KILLER (NK) CELLS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 61
5.1.2 INCREASE IN PATIENT POPULATION WITH CHRONIC DISEASES 61
5.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 62
5.1.4 ADOPTION OF NATURAL KILLER (NK) CELL THERAPY IN EMERGING MARKETS 62
5.2 RESTRAINTS 63
5.2.1 LACK OF SPECIFICITY AND POOR IN-VIVO SURVIVAL OF THE CELLS 63
5.2.2 ADVERSE SIDE EFFECTS OF THERAPIES 63
5.2.3 HIGH COST ASSOCIATED WITH THE THERAPIES 64
5.3 OPPORTUNITIES 65
5.3.1 ADVANCEMENT IN NATURAL KILLER (NK) CELL THERAPIES 65
5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 65
5.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 66
5.4 CHALLENGES 66
5.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 66
5.4.2 LACK OF SPECIFIC TREATMENT BY NATURAL KILLER (NK) CELLS 67
5.4.3 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 67
6 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS 69
6.1 OVERVIEW 70
6.2 NK CELL THERAPIES 73
6.3 NK CELL DIRECTED ANTIBODIES 73
7 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES 75
7.1 OVERVIEW 76
7.2 ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 79
7.3 BISPECIFIC ANTIBODIES 80
8 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION 81
8.1 OVERVIEW 82
8.2 CANCER 85
8.2.1 SOLID TUMORS 86
8.2.2 HEMATOLOGIC MALIGNANCIES 86
8.2.2.1 MULTIPLE MYELOMA 87
8.2.2.2 ACUTE MYELOID LEUKEMIA (AML) 87
8.2.2.3 LYMPHOMA 87
8.2.2.4 OTHERS 87
8.2.3 OTHERS 87
8.3 IMMUNOPROLIFERATIVE DISORDERS 87
8.4 ACUTE INFECTIOUS DISEASES 88
8.5 GASTROINTESTINAL DISEASES 88
8.6 OTHERS 89
9 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 91
9.1 OVERVIEW 92
9.2 HOSPITALS 95
9.3 SPECIALTY CLINICS 95
9.4 RESEARCH & ACADEMIC INSTITUTES 96
10 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 98
10.1 OVERVIEW 99
10.2 HOSPITAL PHARMACIES 102
10.3 DIRECT TENDER 102
10.4 OTHERS 103
11 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION 104
11.1 MIDDLE EAST & AFRICA 105
11.1.1 SAUDI ARABIA 112
11.1.2 SOUTH AFRICA 114
11.1.3 U.A.E 116
11.1.4 ISRAEL 118
11.1.5 KUWAIT 120
11.1.6 EGYPT 122
11.1.7 REST OF MIDDLE EAST & AFRICA 124
12 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELLS THERAPEUTICS MARKET, COMPANY LANDSCAPE 125
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 125
13 SWOT ANALYSIS 126
14 COMPANY PROFILE 127
14.1 MERCK KGAA 127
14.1.1 COMPANY SNAPSHOT 127
14.1.2 RECENT FINANCIALS 127
14.1.3 PRODUCT PORTFOLIO 128
14.1.4 RECENT DEVELOPMENTS 128
14.2 BRISTOL-MYERS SQUIBB COMPANY 130
14.2.1 COMPANY SNAPSHOT 130
14.2.2 RECENT FINANCIALS 130
14.2.3 PRODUCT PORTFOLIO 131
14.2.4 RECENT DEVELOPMENTS 131
14.3 GLYCOSTEM 133
14.3.1 COMPANY SNAPSHOT 133
14.3.2 PRODUCT PORTFOLIO 133
14.3.3 RECENT DEVELOPMENTS 133
14.4 INNATE PHARMA, INC. 135
14.4.1 COMPANY SNAPSHOT 135
14.4.2 REVENUE ANALYSIS 135
14.4.3 PRODUCT PORTFOLIO 136
14.4.4 RECENT DEVELOPMENTS 136
14.5 REGENERON PHARMACEUTICALS INC. 138
14.5.1 COMPANY SNAPSHOT 138
14.5.2 RECENT FINANCIALS 138
14.5.3 PRODUCT PORTFOLIO 139
14.5.4 RECENT DEVELOPMENTS 139
14.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED 140
14.6.1 COMPANY SNAPSHOT 140
14.6.2 RECENT FINANCIALS 140
14.6.3 PRODUCT PORTFOLIO 141
14.6.4 RECENT DEVELOPMENTS 141
14.7 INMUNEBIO 142
14.7.1 COMPANY SNAPSHOT 142
14.7.2 REVENUE ANALYSIS 142
14.7.3 PRODUCT PORTFOLIO 143
14.7.4 RECENT DEVELOPMENTS 143
14.8 KIADIS PHARMA 145
14.8.1 COMPANY SNAPSHOT 145
14.8.2 REVENUE ANALYSIS 145
14.8.3 PRODUCT PORTFOLIO 146
14.8.4 RECENT DEVELOPMENTS 146
14.9 ACEPODIA INC. 148
14.9.1 COMPANY SNAPSHOT 148
14.9.2 PRODUCT PORTFOLIO 148
14.9.3 RECENT DEVELOPMENTS 148
14.10 AFFIMED GMBH 150
14.10.1 COMPANY SNAPSHOT 150
14.10.2 RECENT FINANCIALS 150
14.10.3 PRODUCT PORTFOLIO 151
14.10.4 RECENT DEVELOPMENTS 151
14.11 BIOHAVEN PHARMACEUTICALS 153
14.11.1 COMPANY SNAPSHOT 153
14.11.2 REVENUE ANALYSIS 153
14.11.3 PRODUCT PORTFOLIO 154
14.11.4 RECENT DEVELOPMENTS 154
14.12 BRINK BIOLOGICS, INC. 155
14.12.1 COMPANY SNAPSHOT 155
14.12.2 PRODUCT PORTFOLIO 155
14.12.3 RECENT DEVELOPMENT 155
14.13 CYTOVIA THERAPEUTICS 156
14.13.1 COMPANY SNAPSHOT 156
14.13.2 PRODUCT PORTFOLIO 156
14.13.3 RECENT DEVELOPMENTS 156
14.14 EMERCELL 158
14.14.1 COMPANY SNAPSHOT 158
14.14.2 PRODUCT PORTFOLIO 158
14.14.3 RECENT DEVELOPMENTS 158
14.15 FATE THERAPEUTICS 159
14.15.1 COMPANY SNAPSHOT 159
14.15.2 REVENUE ANALYSIS 159
14.15.3 PRODUCT PORTFOLIO 160
14.15.4 RECENT DEVELOPMENTS 160
14.16 GAMIDA CELL 162
14.16.1 COMPANY SNAPSHOT 162
14.16.2 PRODUCT PORTFOLIO 162
14.16.3 RECENT DEVELOPMENTS 163
14.17 ICELL GENE THERAPEUTICS 164
14.17.1 COMPANY SNAPSHOT 164
14.17.2 PRODUCT PORTFOLIO 164
14.17.3 RECENT DEVELOPMENT 164
14.18 IMMUNITYBIO, INC. 165
14.18.1 COMPANY SNAPSHOT 165
14.18.2 REVENUE ANALYSIS 165
14.18.3 PRODUCT PORTFOLIO 166
14.18.4 RECENT DEVELOPMENTS 166
14.19 MULTIMMUNE GMBH 167
14.19.1 COMPANY SNAPSHOT 167
14.19.2 PRODUCT PORTFOLIO 167
14.19.3 RECENT DEVELOPMENTS 167
14.20 NEKTAR 168
14.20.1 COMPANY SNAPSHOT 168
14.20.2 REVENUE ANALYSIS 168
14.20.3 PRODUCT PORTFOLIO 169
14.20.4 RECENT DEVELOPMENTS 169
14.21 NKARTA, INC. 170
14.21.1 COMPANY SNAPSHOT 170
14.21.2 PRODUCT PORTFOLIO 170
14.21.3 RECENT DEVELOPMENTS 170
14.22 PERSONGEN BIOTHERAPEUTICS 172
14.22.1 COMPANY SNAPSHOT 172
14.22.2 PRODUCT PORTFOLIO 172
14.22.3 RECENT DEVELOPMENTS 172
14.23 PHIO PHARMACEUTICALS 174
14.23.1 COMPANY SNAPSHOT 174
14.23.2 PRODUCT PORTFOLIO 174
14.23.3 RECENT DEVELOPMENTS 174
15 QUESTIONNAIRE 176
16 RELATED REPORTS 180
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
